Table 2.

CNGs in HAS and CGC tumour tissues

Chr	Gene	Start	End	Location	HAS	CGC
1	MAPKAPK2	206,858,607	206,906,131	1q32.1	2 (8.7%)	0
5	SKP2	36,152,269	36,184,167	5q13.2	2 (8.7%)	0
5	RICTOR	38,942,343	39,074,534	5p13.1	2 (8.7%)	0
5	PRKAA1	40,762,862	40,798,318	5p13.1	2 (8.7%)	0
6	VEGFA	43,738,337	43,752,308	6p21.1	6 (26.1%)	2 (11.1%)
11	GSTP1	67,351,215	67,354,073	11q13.2	2 (8.7%)	0
19	CCNE1	30,303,540	30,314,742	19q12	5 (21.7%)	1 (5.6%)
20	ASXL1	30,947,042	31,025,167	20q11.21	2 (8.7%)	0
20	TPX2	30,345,213	30,388,947	20q11.21	2 (8.7%)	0
20	E2F1	32,264,522	32,274,027	20q11.22	3 (13.0%)	0
20	SRC	36,012,542	36,031,797	20q11.23	2 (8.7%)	0
20	TOP1	39,657,979	39,752,005	20q12	11 (47.8%)	0
20	STK4	43,595,147	43,703,877	20q13.12	10 (43.5%)	0
20	NCOA3	46,250,933	46,282,315	20q13.12	2 (8.7%)	0
20	SRMS	62,172,142	62,178,838	20q13.33	2 (8.7%)	0
20	PTK6	62,160,863	62,168,692	20q13.33	2 (8.7%)	0
20	ARFRP1	62,331,739	62,338,496	20q13.33	2 (8.7%)	0
20	FKBP1A	1,350,615	1,373,612	20q13	2 (8.7%)	0
17	ERBB2	37,855,747	37,884,319	17q12	1 (4.3%)	3 (16.7%)
17	CDK12	37,618,308	37,687,592	17q12	0 (0.0%)	3 (16.7%)
12	ERBB3	56,474,026	56,495,855	12q13.2	0 (0.0%)	2 (5.6%)